ライフサイエンスコーパス: cynomolgus

1 t CP 55 940 in Old World monkeys (rhesus and cynomolgus), a species that has been used extensively in

2 over 6months at sufficient levels to protect Cynomolgus against laser-induced grade IV choroidal neov

3 resolved by sequence-based typing of rhesus, cynomolgus and pig-tailed macaques, nearly half of which

4 he key host factor limiting HBV infection in cynomolgus and rhesus macaques and in pigs.

5 Both cynomolgus and rhesus macaques developed mild fevers aft

6 gene expression in the genital tract in both cynomolgus and rhesus macaques.

7 Resistance decreased in both cynomolgus and rhesus monkeys as total volume perfused i

8 traceptive end points in the rat and also in cynomolgus and rhesus monkeys including ovulation inhibi

9 lities of the three macaque species (rhesus, cynomolgus, and bonnet) used.

10 We show for the first time that the mouse, cynomolgus, and human cross-reactive, antagonistic anti-

11 we engineered pH-sensitive binding to mouse, cynomolgus, and human PCSK9 into J16, resulting in J17.

12 A similarly selected anti-cynomolgus CD40 dAb recognizing the homologous epitope i

13 monkey and 21 from human, were screened with cynomolgus DNA samples.

14 In an alternative approach, we genotyped 100 cynomolgus DNAs using a rhesus macaque SNP array represe

15 owed decreased binding affinity to human and cynomolgus FcgammaRs compared with the wild-type IgG1 an

16 structures of AFD in complex with human and cynomolgus FD (at 2.4 and 2.3 A, respectively) revealed

17 To balance this shift toward activation, the cynomolgus inhibitory FcgammaRIIb shows strongly increas

18 sults in prolonged, drug-free engraftment of cynomolgus islet allografts.

19 characterization of the proteome response in cynomolgus macaque (Macaca fascicularis) lung tissue ove

20 We used the cynomolgus macaque (Macaca fascicularis) model of HIV-My

21 The cynomolgus macaque (Macaca fascicularis) model of M. tub

22 We developed an intradermal (ID) challenge cynomolgus macaque (Macaca fascicularis) model of scrub

23 Using the cynomolgus macaque (Macaca fascicularis) to assess prima

24 ectomized non-human primate (NHP) model, the cynomolgus macaque (Macaca fascicularis).

25 the utility of cigarette smoke (CS)-exposed cynomolgus macaque as a nonhuman primate (NHP) large ani

26 Male cynomolgus macaque donor-recipient pairs were selected b

27 ow that TGN1412 binds similarly to human and cynomolgus macaque FcgammaR, eliminating the possibility

28 Inhalational plague in the cynomolgus macaque inoculated by the aerosol route produ

29 of the SOIV, we used a recently established cynomolgus macaque model and compared parameters of clin

30 We used the cynomolgus macaque model of TB to demonstrate that ex vi

31 evaluated the gene expression changes in the cynomolgus macaque model of TB, which recapitulates all

32 ociated with arenavirus virulence, we used a cynomolgus macaque model to evaluate the pathogenesis of

33 We applied this strategy in a Cynomolgus macaque model.

34 Cynomolgus macaque monkeys were trained to perform memor

35 of EBOV infection, EBOTAb was tested in the cynomolgus macaque non-human primate model of lethal EBO

36 he first time, to our knowledge, that LCs in cynomolgus macaque skin are capable of inducing antivira

37 However, in the cynomolgus macaque stomach tissue, the expression patter

38 on of a natural classical scrapie isolate to cynomolgus macaque, a highly relevant model for human pr

39 The cynomolgus macaque, Macaca fascicularis, was introduced

40 transduction after injection into a newborn cynomolgus macaque.

41 , using iPSCs derived from an MHC homozygous cynomolgus macaque.

42 NPs from some of the same genomic regions of cynomolgus macaques (from Indochina, Indonesia, Mauritiu

43 HBV-positive markers were detected in cynomolgus macaques (Macaca fascicularis) from Mauritius

44 Compared to cynomolgus macaques (Macaca fascicularis) infected with

45 and functional genomics tools, we studied 34 cynomolgus macaques (Macaca fascicularis) to compare a 2

46 Telemetered cynomolgus macaques (Macaca fascicularis) were challenge

47 campal bioenergetic capacity in adult female cynomolgus macaques (Macaca fascicularis).

48 We recently showed that Mauritian cynomolgus macaques (MCM) have unusually simple MHC gene

49 in rhesus macaques (RM) and Mauritian-origin cynomolgus macaques (MCM).

50 pecific CD8 T cells from SIV-naive Mauritian cynomolgus macaques (MCM).

51 nses to Mycobacterium tuberculosis Mauritian cynomolgus macaques (MCMs) are a unique group of animals

52 nce variants in SIVmac239-infected Mauritian cynomolgus macaques (MCMs) that are homozygous for the M

53 immunodeficiency virus (SIV) from Mauritian cynomolgus macaques (MCMs) that were homozygous and hete

54 In this study, we used male cynomolgus macaques (n=15) living in established social

55 Cynomolgus macaques 4 years of age or older were infecte

56 Using voltammetry in brain slices from cynomolgus macaques after 6 months of ad libitum ethanol

57 ival of SUDV challenge did not fully protect cynomolgus macaques against intramuscular EBOV back-chal

58 Here we show that both rhesus and cynomolgus macaques are highly susceptible to infection

59 CyTOF Abs to compare the B cell response in cynomolgus macaques at baseline, and 8 and 28 d after th

60 unodeficiency virus (SIV)/DeltaB670 infected cynomolgus macaques at different stages of infection.

61 n understanding ZEBOV-Makona pathogenesis in cynomolgus macaques by measuring changes in immune cell

62 simian immunodeficiency virus (SIV)-infected cynomolgus macaques by use of polymerase chain reaction

63 r demonstrate that loci defined in Mauritian cynomolgus macaques can be applied to rhesus macaques.

64 Neutralization of TNF in latently infected cynomolgus macaques caused reactivation in a majority of

65 h BCG delays and reduces clinical disease in cynomolgus macaques challenged with M. tuberculosis and

66 tuberculosis infection, equal proportions of cynomolgus macaques develop active disease or latent inf

67 Control cynomolgus macaques developed fever, classic eschars, ly

68 We studied cynomolgus macaques exposed to Ebola virus Makona via di

69 ost importantly, BCX4430 completely protects cynomolgus macaques from Marburg virus infection when ad

70 tions and event-related potentials (ERPs) in Cynomolgus macaques fully trained to perform a continuou

71 studies which illustrate how the rhesus and cynomolgus macaques have enriched and may continue to ad

72 tion of different human smallpox vaccines in cynomolgus macaques helps to provide information about o

73 us monoclonal antibodies (MAbs) derived from cynomolgus macaques immunized repeatedly with a mixture

74 Comparisons of SNP profiles from cynomolgus macaques imported from breeding centers in Ch

75 inistration of the equine IgG over 5 days to cynomolgus macaques infected 24 hours previously with a

76 Cynomolgus macaques infected ocularly with a trachoma st

77 In cynomolgus macaques infected with a low dose of M. tuber

78 Cynomolgus macaques infected with low-dose Mycobacterium

79 riable course of disease is recapitulated in cynomolgus macaques infected with Mtb.

80 As an example, cynomolgus macaques obtained from 2 different breeding c

81 ttle is known about the genomic variation in cynomolgus macaques or how the sequence variants compare

82 t on natural, persisting HBV infection among cynomolgus macaques provides the first evidence for the

83 M. tuberculosis infection in cynomolgus macaques recapitulates essentially all aspect

84 ose challenge with fully virulent strains in cynomolgus macaques result in the full clinical spectrum

85 dose Mycobacterium tuberculosis infection in cynomolgus macaques results in a spectrum of disease sim

86 ation of aerosolized H5N1 influenza virus in cynomolgus macaques results in fulminant pneumonia that

87 ious genetic studies have reported Mauritian cynomolgus macaques to be panmictic, the individuals inc

88 ntibodies from vaccinated Ebola virus-immune cynomolgus macaques to naive macaques failed to confer p

89 1 viruses and compared the host responses of cynomolgus macaques to the virus infection.

90 Cynomolgus macaques vaccinated with COBRA clade 2 HA H5N

91 Disease caused by MARV in cynomolgus macaques was very similar to disease previous

92 Chronically SHIV89.6P-infected cynomolgus macaques were CD8(+) cell-depleted, and the f

93 Groups of cynomolgus macaques were depleted of CD4+ T, CD8+ T, or

94 Cynomolgus macaques were exposed by inhalation to approx

95 Cynomolgus macaques were exposed to aerosolized monkeypo

96 Eight Mauritian derived, MHC-typed cynomolgus macaques were immunised with 10(5) TCID(50) o

97 Cynomolgus macaques were infected with MARV Angola and m

98 mice, rats, dogs, pigs, rhesus macaques, and cynomolgus macaques were transduced with adeno-associate

99 ) protected 67% (6 of 9) and 25% (1 of 4) of cynomolgus macaques when administered 30 minutes and 24

100 VRP expressing SUDV GP completely protected cynomolgus macaques when challenged with aerosolized SUD

101 des of Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at advan

102 w that chemoprophylaxis of latently infected cynomolgus macaques with 6 mo of isoniazid (INH) effecti

103 Vaccination of cynomolgus macaques with a single dose of either vaccine

104 cumulation of mutations in Mtb isolated from cynomolgus macaques with active, latent or reactivated d

105 induce severe disease in humans, we infected cynomolgus macaques with six different H5N1 strains isol

106 infected MHC-homozygous and MHC-heterozygous cynomolgus macaques with the pathogenic virus SIVmac239.

107 Intratracheal infection of cynomolgus macaques with these recombinant viruses revea

108 A single intramuscular vaccination of cynomolgus macaques with VRP expressing SUDV GP provided

109 an primates (NHPs; African green monkeys and cynomolgus macaques) harbor serosal B cells expressing a

110 brains of rats and adult nonhuman primates (cynomolgus macaques).

111 of anti-rLcrV and anti-rV10 immune sera from cynomolgus macaques, BALB/c mice, and brown Norway rats

112 ection rapidly and profoundly impacts DCs in cynomolgus macaques, increasing the number of blood myel

113 Contrarily, hepatocytes from cynomolgus macaques, rhesus macaques, and pigs became fu

114 ons derived from RNA-seq data for rhesus and cynomolgus macaques, two of the most commonly used NHP m

115 histocompatibility complex-matched Mauritian cynomolgus macaques, we did not detect SIV-specific func

116 g MHC-homozygous and -heterozygous Mauritian cynomolgus macaques, we have now obtained evidence that

117 ly restricted genetic diversity of Mauritian cynomolgus macaques, we performed adoptive transfers bet

118 smallpox, a monkeypox model of infection in cynomolgus macaques, which simulates smallpox in humans,

119 ema toxin after pulmonary spore challenge of cynomolgus macaques.

120 agglutinin (HA) and/or nucleoprotein (NP) in cynomolgus macaques.

121 idually or in combination (V/W/E) to mice or cynomolgus macaques.

122 e conserved across FcgammaRIIb of rhesus and cynomolgus macaques.

123 nrelated, fully MHC-matched Mauritian-origin cynomolgus macaques.

124 assa fever: inbred strain 13 guinea pigs and cynomolgus macaques.

125 scular challenge with either SUDV or EBOV in cynomolgus macaques.

126 cell responses in acutely infected Mauritian cynomolgus macaques.

127 in combination, via the intranasal route in cynomolgus macaques.

128 lammatory cytokine release in the airways of cynomolgus macaques.

129 cell responses in MHC-I homozygous Mauritian cynomolgus macaques.

130 e and creatine kinase serum enzyme levels in cynomolgus macaques.

131 nted to mixed lymphocyte reaction-mismatched Cynomolgus macaques.

132 nhances the activity of LCAT from humans and cynomolgus macaques.

133 on between Lujo and Lassa virus infection in cynomolgus macaques.

134 pecific CD8 T cells from SIV-naive Mauritian cynomolgus macaques.

135 olume in behaviorally depressed adult female cynomolgus macaques; the mechanisms contributing to that

136 ariants conferring extended plasma t1/2 In a cynomolgus model of T cell-dependent Ab response, the CT

137 Here, we analyzed cynomolgus monkey (CM) iPSC-derived midbrain dopamine ne

138 ve state in a non-human primate species, the cynomolgus monkey (Macaca fascicularis), in a realistic

139 ge average: 41 +/- 17 years; range: 6-7) and cynomolgus monkey (n = 19; age average: 7.7 +/- 1.8 year

140 264RAD cross-reacts with human, mouse and cynomolgus monkey alphavbeta6, and inhibits binding to a

141 omolgus monkey of those derivatives with low cynomolgus monkey and human intrinsic clearance gave 2',

142 flammatory cytokine induction pathway in the cynomolgus monkey and humans, but not observed systemica

143 to 10,000-fold for CYP1A1 in vivo in rat and cynomolgus monkey and up to 45-fold for CYP1A1 and CYP1A

144 kGH was administered to mice, rabbits, and a cynomolgus monkey by subcutaneous or intradermal injecti

145 Postmortem cynomolgus monkey eyes (n = 14; age range, 3.0-11.5 year

146 in cultured anterior segments of rhesus and cynomolgus monkey eyes.

147 lecules and their SEFL variants to human and cynomolgus monkey FcgammaRs were evaluated using flow cy

148 ults for human IgG2 and IgG4 obtained in the cynomolgus monkey have to be cautiously interpreted, whe

149 Cynomolgus monkey heterotopic cardiac allograft recipien

150 nd effector functions, whereas, in contrast, cynomolgus monkey IgG2 and IgG4 display strong effector

151 dies were assessed in a variety of human and cynomolgus monkey in vitro assays.

152 -MS/MS assay for quantification of human and cynomolgus monkey interleukin 21 (IL-21) was developed,

153 The cynomolgus monkey lens retains a significant fraction of

154 In an acute cynomolgus monkey model of interleukin 6 (IL-6)-induced

155 el of fatal tuberculosis and the established cynomolgus monkey model to design an immuno-chemotherape

156 evaluated Mtb72F formulated in AS02A in the cynomolgus monkey model.

157 One live delivery of a female cynomolgus monkey occurred after 162 days of gestation,

158 pharmacokinetic profile in the rat, dog, and cynomolgus monkey of those derivatives with low cynomolg

159 totoxicity in vitro against Daudi cells with cynomolgus monkey peripheral blood mononuclear cells, an

160 dentified in 96 h and 168 h postdose in vivo cynomolgus monkey plasma.

161 antibody-dependent monocyte phagocytosis of cynomolgus monkey platelets, and cynomolgus platelet act

162 secondary lymphoid organs, and the graft in cynomolgus monkey recipients of heterotopic cardiac allo

163 Cynomolgus monkey recipients of life-supporting kidney a

164 uence of alemtuzumab (i) on ex vivo-expanded cynomolgus monkey regulatory T cells (Treg) generated fo

165 say was developed and qualified in human and cynomolgus monkey serum and tissues with a lower limit o

166 antibody and those derived from proteins in cynomolgus monkey serum with either d(2)- or d(0)-formal

167 uantify a recombinant monoclonal antibody in cynomolgus monkey serum.

168 However, IL-21 levels were quantified in cynomolgus monkey spleen and colon tissue and normal and

169 ime profile after oral administration in the cynomolgus monkey that showed a very low peak-to-trough

170 acokinetics of two human IgG1 Fc variants in cynomolgus monkey to further clarify the affinity-pharma

171 Thus, expanded cynomolgus monkey Treg are resistant to alemtuzumab-medi

172 the pharmacokinetic study of a mAb dosed in cynomolgus monkey, and the results were compared with th

173 d 8 has good oral bioavailability in rat and cynomolgus monkey, attractive overall preclinical proper

174 pproximately 2-fold decrease in clearance in cynomolgus monkey, supporting the notion that modest inc

175 erated and confirmed to be cross-reactive to cynomolgus monkey.

176 IIb, but show higher levels of FcgammaRII in cynomolgus monkey.

177 gG1 antibody to oxidized LDL (anti-oxLDL) in cynomolgus monkey.

178 n promising oral bioavailability in rats and cynomolgus monkey.

179 inding, and radiation dosimetry in a healthy cynomolgus monkey.

180 A PET study was performed on a cynomolgus monkey.

181 ements were performed on ex vivo lenses from cynomolgus monkeys (cyno: n = 120; age, 2.7-14.3 years),

182 cine and human therapeutic Ab development in cynomolgus monkeys (cynos) are influenced by immune resp

183 ic (PK) behavior of monoclonal antibodies in cynomolgus monkeys (cynos) is generally translatable to

184 its a robust acute pharmacodynamic effect in cynomolgus monkeys (ED50 0.12 mg/kg) and in DIO mice.

185 Cynomolgus monkeys (Macaca fascicularis) were immunized

186 SEARCH DESIGN AND At baseline, 32 male adult cynomolgus monkeys (Macaca fascicularis) were randomized

187 isms of spread, we infected groups of 5 or 6 cynomolgus monkeys (Macaca fascicularis) with either a w

188 ropic Mycoplasma sp. in a research colony of cynomolgus monkeys (Macaca fascicularis).

189 injected into the mammillary bodies of five cynomolgus monkeys (Macaca fascicularis).

190 receptor availability was assessed in female cynomolgus monkeys (n = 16) with positron emission tomog

191 was IC-injected into rats (n = 72 eyes) and cynomolgus monkeys (n = 3).

192 In a group of cocaine-experienced male cynomolgus monkeys (N=4), THC SA was examined under a se

193 e performed in rats (organ distribution) and cynomolgus monkeys (PET/CT imaging) to determine the GLP

194 ure perfusion in one eye of 22 rhesus and 17 cynomolgus monkeys (ranging in age, respectively, from 4

195 e target tissues, liver, and adipose, and in cynomolgus monkeys a 10 mg/kg oral dose reduced cortisol

196 Cynomolgus monkeys administered ISIS 416858 (4, 8, 12, a

197 n and thrombus detection was investigated in cynomolgus monkeys after insertion of a roughened cathet

198 lethal Zaire Ebola virus (ZEBOV) and 100% of cynomolgus monkeys against Lake Victoria Marburg virus (

199 r experience with severe sepsis in two young cynomolgus monkeys and five pigs that were subjected to

200 ormed 305 ovarian stimulations in 128 female cynomolgus monkeys and found that ovarian stimulation ca

201 of (11)C-Lu AE92686 in the striatum of both cynomolgus monkeys and humans were evaluated by the simp

202 or PDE10A-expressing regions in the brain of cynomolgus monkeys and humans.

203 6 was evaluated as a PET tracer candidate in cynomolgus monkeys and in humans.

204 TT30 selectively inhibits CAP in cynomolgus monkeys and is bioavailable after subcutaneou

205 erapy functionality of SiGdNP were tested in cynomolgus monkeys and pancreatic tumor-bearing mice mod

206 ound 6 had minimal effect on HDL-C levels in cynomolgus monkeys and showed human cadaver skin permeab

207 ibose (ADPR) and ADP in colonic muscles from cynomolgus monkeys and wild-type (CD38(+/+)) and CD38(-/

208 nge in resistance significantly increased in cynomolgus monkeys as total volume perfused increased (0

209 d higher titers of toxin-neutralizing Abs in cynomolgus monkeys at 2 wk compared with animals immuniz

210 tional to Delta n(RNFL)) was measured in two cynomolgus monkeys by enhanced polarization-sensitive op

211 ribution of (125)I-AMG 386 was determined in cynomolgus monkeys by whole-body autoradiography and rad

212 way-derived cells from Ascaris suum-allergic cynomolgus monkeys did not produce appreciable TNF-alpha

213 mouse models of human lymphoma and in normal cynomolgus monkeys disclosed that low doses of veltuzuma

214 ng data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucag

215 DX-2930 injected subcutaneously into cynomolgus monkeys exhibited a long half-life (t(1/2) ap

216 ered CSF and cortex Abeta40 in both rats and cynomolgus monkeys following a single oral dose.

217 odels required dosing every 48 h, studies in cynomolgus monkeys indicate that less frequent dosing ma

218 The pharmacologic profile in cynomolgus monkeys is equivalent to what was reported in

219 A single administration of 27C3 to cynomolgus monkeys led to a rapid increase of plasma LCA

220 CR in cynomolgus monkeys may alter insulin signaling in vivo b

221 aft SCID mouse model and depletes B cells in cynomolgus monkeys more efficiently.

222 dation of a humanized monoclonal antibody in cynomolgus monkeys over a time period of 12 weeks after

223 given to rhesus macaques on days 42 and 225; cynomolgus monkeys received a booster with either PA or

224 man (h)FcRn transgenic mice and threefold in cynomolgus monkeys retain efficacy at longer dosing inte

225 and phenotypes of TALEN-edited MECP2 mutant cynomolgus monkeys serving as a model for a neurodevelop

226 ging with [(18)F]9-[(18)F]11 in anesthetized cynomolgus monkeys showed high uptake in the putamen wit

227 ic studies in human FcRn transgenic mice and cynomolgus monkeys showed that multiple variants with in

228 Administration of bardoxolone methyl to cynomolgus monkeys significantly decreased the protein e

229 it is tolerated at higher doses in rats and cynomolgus monkeys than the same conjugate prepared by c

230 , we evaluated T and B cell alloresponses in cynomolgus monkeys that had received combined kidney/bon

231 ST101 were studied in 3xTg-AD mice and young cynomolgus monkeys using a combination of biochemical an

232 development of allergic lung inflammation in cynomolgus monkeys using gene expression profiling and t

233 Cynomolgus monkeys were fed brain of (eleven) cows with

234 Eighteen cynomolgus monkeys were infected with MARV; blood and ti

235 To address this question, cynomolgus monkeys were injected i.v. with two doses of

236 In this study, 11 cynomolgus monkeys were vaccinated with a blended vaccin

237 (DKO) pig (and a GGTA1-KO pig) and immunized cynomolgus monkeys with both of these cells.

238 Interestingly, treatment of cynomolgus monkeys with JNJ-61186372 resulted in no majo

239 In cynomolgus monkeys, a single injection of mAb1 reduces s

240 PMNs to LukGH was similar between humans and cynomolgus monkeys, and was greater than that of rabbits

241 alyzed 15 pairs of pregnant and non-pregnant cynomolgus monkeys, each pair of which received embryos

242 of B cells prior to heart transplantation in cynomolgus monkeys, in addition to conventional posttran

243 o by binding to endogenous PCSK9 in mice and cynomolgus monkeys, respectively.

244 rance of 19.3 and 15.5 mL/min/kg in rats and cynomolgus monkeys, respectively.

245 In cynomolgus monkeys, SGN-CD19B effectively depleted CD20(

246 In cynomolgus monkeys, the anti-CD28 dAb demonstrated pharm

247 ed hamsters, human CETP transgenic mice, and cynomolgus monkeys, the in vivo efficacy of 12 for raisi

248 In cynomolgus monkeys, we again observed a short half-life,

249 was advanced into a pharmacodynamic model in cynomolgus monkeys, where it inhibited adipose 11beta-HS

250 electrocardiogram parameters in telemetrized cynomolgus monkeys.

251 al mice, mice transgenic for human FcRn, and cynomolgus monkeys.

252 inding protein 2 (MECP2), in both rhesus and cynomolgus monkeys.

253 r cell-mediated killing assay and in vivo in cynomolgus monkeys.

254 tal, 10 PET measurements were conducted on 5 cynomolgus monkeys.

255 I and demonstrated to modulate serum iron in cynomolgus monkeys.

256 on in livers of mice, rats, and dogs but not cynomolgus monkeys.

257 optic nerve margin in the right eyes of four cynomolgus monkeys.

258 hippocampal IRS-1pSer and JNK activation in cynomolgus monkeys.

259 d both blood and bone marrow plasma cells in cynomolgus monkeys.

260 tic cleavage of FGF21 identified in mice and cynomolgus monkeys.

261 ghtly higher than typical IgG1 antibodies in cynomolgus monkeys.

262 e, and selectively reduce LDL-cholesterol in cynomolgus monkeys.

263 labeled material) to two male and two female cynomolgus monkeys.

264 us-sensitive, CD155 transgenic (tg) mice and cynomolgus monkeys.

265 e, after accounting for total volume, in the cynomolgus monkeys.

266 f total volume were determined in rhesus and cynomolgus monkeys.

267 heavy drinking within the inferior olive of cynomolgus monkeys.

268 ogenitor, CAT6001, in a single-dose study in cynomolgus monkeys.

269 rior cingulate cortex (ACC; Area 24) of male cynomolgus monkeys.

270 b/CD18 prevents progression of AKI to CKD in cynomolgus monkeys.

271 f PMNs from the bone marrow of both mice and cynomolgus monkeys.

272 nd pharmacokinetic analysis was performed in cynomolgus monkeys.

273 e different serum pools from male and female cynomolgus monkeys.

274 surgically menopausal young and middle-aged cynomolgus monkeys.

275 n of B cells and bone marrow plasma cells in cynomolgus monkeys.

276 properties of 12p were assessed in rats and Cynomolgus monkeys.

277 tive primer and probe sets ever reported for cynomolgus monkeys.

278 ow background after intravenous injection in cynomolgus monkeys.

279 n stimulated gene (ISG) response in mice and cynomolgus monkeys.

280 bies virus-based EBOV vaccine, in rhesus and cynomolgus monkeys.

281 poor pharmacokinetic profile in both rat and cynomolgus monkeys.

282 to identify recently derived retrocopies in cynomolgus monkeys.

283 increased circulating intact FGF21 levels in cynomolgus monkeys.

284 retrocopies, all of which are polymorphic in cynomolgus monkeys.

285 ing strength of cocaine in group-housed male cynomolgus monkeys.

286 erapeutic target for autoimmune diseases, in cynomolgus monkeys.

287 d reduces fever after sublethal challenge in cynomolgus monkeys.

288 administration to lipopolysaccharide-treated cynomolgus monkeys.

289 ld prolonged half-life in mice, rabbits, and cynomolgus monkeys; however, the prolongation was less p

290 plasma from chimpanzees; gorillas; bonobos; cynomolgus monkeys; wild-type, apoE(-/-), LDLR(-/-), and

291 Cynomolgus MSCs were obtained from iliac crest aspirate

292 monstration of efficacy in the gold standard cynomolgus or rhesus macaque models of filovirus infecti

293 GLP-1R occupancy in the cynomolgus pancreas after coinjection of DO3A-exendin-4

294 GLP-1R occupancy in the cynomolgus pancreas was quantified with a 1-tissue-compa

295 Results:(18)F-BMS-986192 bound to human and cynomolgus PD-L1 with a dissociation constant of less th

296 ocytosis of cynomolgus monkey platelets, and cynomolgus platelet activation in vitro These experiment

297 ciency virus-infected rhesus with AIDS and 1 cynomolgus post-transplant selected with SV40 brain infe

298 titative LC/MS to determine ADA in human and cynomolgus serum in the presence of high circulating con

299 Both the human-specific and cynomolgus-specific molecules remain pure antagonists ev

300 CP2-targeting TALEN plasmids into rhesus and cynomolgus zygotes leads to effective gene editing of ME